20 results
IBS-C Pharmacotherapy

Polyethylene glycol
Lubiprostone
Linaclotide
Plecanatide
Tegaserod
Tenapanor

#IBSC #IBS #Constipation #Irritable #Bowel #Syndrome #pharmacology #table #comparison #management #treatment
Irritable #Bowel #Syndrome ... #pharmacology # ... table #comparison ... #management #treatment
IBS-D Pharmacotherapy

Loperamide
Rifaximin
Eluxadoline
Alosetron
Antispasmodics
Tricyclic antidepressants
SSRIs

#IBSD #IBS #Diarrhea #Irritable #Bowel #Syndrome #pharmacology #table #comparison #management #treatment
Irritable #Bowel #Syndrome ... #pharmacology # ... table #comparison ... #management #treatment
Myelodysplastic Syndrome (MD) - Diagnosis and Management Summary
myelo (marrow) -dys- (abnormal) -plastic (shape) = funny-shaped cells
Myelodysplastic Syndrome ... only curative treatment ... Myelodysplastic #Syndrome ... #treatment #hematology ... #oncology
Irritable Bowel Syndrome (IBS) Treatment Options
Amitiza (Lubiprostone)
Antidepressants: Celexa, Wellbutrin, Prozac, Paxil, Nortriptyline, and Zoloft
Bentyl (Dicyclomine)
Creon
Ducolax
Imodium, Maalox,
Irritable Bowel Syndrome ... (IBS) Treatment ... #constipation #management ... #pharmacology # ... table
Managing warfarin INR

Warfarin dosage must be individualized according to the patient's response to the drug, and
#management #algorithm ... #pharmacology # ... treatment #medications ... #table #pharmacotherapy ... decisionaid #cardiology #hematology
Behcet's Syndrome - Treatment
Ulcers:
 • Treatment: Topical steroids
 • Prevention: Colchicine
 • Azathioprine for refractory disease
Arthritis:
Behcet's Syndrome ... Behcets #disease #Syndrome ... #Treatment #management ... #pharmacology # ... rheumatology
IDSA 2017 CDiff Guidelines - Table 7. Potential Treatment Agents for Treatment of the Primary Clostridium difficile
IDSA 2017 CDiff ... Guidelines - Table ... Potential Treatment ... infection Episode #Pharmacology ... #Management #CDiff
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
IDSA Recommendations ... mucoadhesive buccal tablet ... chew, or crush tablet ... #management #opportunistic ... infections #HIVAIDS #pharmacology
(DOAC interactions) Cancer-treatment specific inducers (↑) and inhibitors (↓)
of cytochrome p450 CYP3A4 and P-glycoprotein.

DOACs are substrates
interactions) Cancer-treatment ... #Chemotherapy #Oncology ... #Hematology #Interactions ... #Table #Pharmacology
Differentiation Syndrome in APML
Epidemiology:
 • Incidence: common in APL (2-48% depending on the study)
 • Triggers:
Differentiation Syndrome ... Triggers: ATRA treatment ... Renal Failure Treatment ... APML #diagnosis #management ... #hematology #oncology